Freddie Dear

Freddie Dear is a seasoned professional in corporate development and investment management with a robust background in the biotech and therapeutic sectors. Currently serving as VP of Corporate Development at Ascend and Principal at Monograph Capital, Freddie Dear also holds the role of Investor Director at Nocion Therapeutics, Inc. Previous experience includes positions as a Board Observer at Clade Therapeutics, Forcefield Therapeutics, and Quell Therapeutics, as well as serving as an Investment Partner at Syncona Limited. A graduate of The University of Edinburgh, Freddie Dear earned a Bachelor of Science in Biochemistry and has also gained experience through various internships and roles, including time at Wellcome Trust and Tetragon Financial Group Limited.